News – Page 1175 – Endpoints News

What PDUFA date? Clovis shares surge as PARPs get trendy on Wall Street

9 years ago

Neoantigens beckon Merck into a $200M cancer collaboration with Moderna

9 years ago

Galena implodes as trial monitors call a halt to a failed PhIII cancer study

9 years ago

Tesaro rockets up after PARP inhibitor aces PhIII study and R&D rivalry intensifies

9 years ago

Esperion tanks on warning that the road to an FDA decision could be much, much longer than they thought

9 years ago

Two flops in two weeks for Marinus Pharmaceuticals' ganaxolone

9 years ago

Troubled Infinity axes 100 staffers, shutters trials and rewards top execs after AbbVie walks away from deal

9 years ago

In latest setback for stem cell sector, Celyad fails PhIII— and the biotech claims a victory

9 years ago

Novartis inks a $2.5B bispecific cancer drug development alliance with Xencor

9 years ago

Regulus craters after FDA slaps a hold on hep C RNA drug following 2nd case of jaundice

9 years ago

Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

9 years ago

Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up

9 years ago

GW Pharma’s rally rolls on as cannabinoid drug scores again in PhIII Epidiolex anti-convulsive study

9 years ago

The Zerhouni rule: “Every company that acquires a platform company kills it.”

9 years ago

Scoring the 5 top phase III drugs in the global pipeline

9 years ago

IPO bound? CRISPR Therapeutics ups B round to a cool $140M

9 years ago

Medivation to Sanofi (in translation): You don't know beans about cancer drug development(!)

9 years ago

What’s ahead for UK biotechs in the wake of Brexit? It's not a pretty picture

9 years ago

These 300(+) Biotech Twitter citizens are the quickest to tweet news

9 years ago

VC giant NEA backs an upstart’s plan to tackle neurodegeneration

9 years ago

Ebola! Zika! ATM! Inovio CEO Kim called out for gaming pandemic panic

9 years ago

Zombie biotech Eleven Bio sheds staff in the final wind down

9 years ago

Is Biogen the most desperate buyer scouting the biotech market?

9 years ago

Celgene pays $50M to tie up with four big cancer research centers

9 years ago

First page Previous page 1172 1173 117411751176 Next page Last page